138 related articles for article (PubMed ID: 34882512)
1. mRNA and small RNA gene expression changes in peripheral blood to detect internal Ra-223 exposure.
Ostheim P; Miederer M; Schreckenberger M; Nestler T; Hoffmann MA; Lassmann M; Eberlein U; Barsegian V; Rump A; Majewski M; Port M; Abend M
Int J Radiat Biol; 2022; 98(5):900-912. PubMed ID: 34882512
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
3. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
4. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
5. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
7. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
Ann Nucl Med; 2019 Mar; 33(3):211-221. PubMed ID: 30484260
[TBL] [Abstract][Full Text] [Related]
8. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
10. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
Carrasquillo JA; O'Donoghue JA; Pandit-Taskar N; Humm JL; Rathkopf DE; Slovin SF; Williamson MJ; Lacuna K; Aksnes AK; Larson SM; Scher HI; Morris MJ
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1384-93. PubMed ID: 23653243
[TBL] [Abstract][Full Text] [Related]
12. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
13. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
14. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
[TBL] [Abstract][Full Text] [Related]
15. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
16. Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy.
Bastiani I; McMahon SJ; Turner P; Redmond KM; McGarry CK; Cole A; O'Sullivan JM; Prise KM; Ainsbury L; Anderson R
Nucl Med Biol; 2022; 106-107():10-20. PubMed ID: 34968973
[TBL] [Abstract][Full Text] [Related]
17. Extraction of
Großer OS; Wissel H; Wallbaum T; Genseke P; Kupitz D; Ricke J; Ruf J; Amthauer H
Nuklearmedizin; 2017 Jun; 56(3):69-72. PubMed ID: 28383088
[TBL] [Abstract][Full Text] [Related]
18. Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Dauer LT; Williamson MJ; Humm J; O'Donoghue J; Ghani R; Awadallah R; Carrasquillo J; Pandit-Taskar N; Aksnes AK; Biggin C; Reinton V; Morris M; St Germain J
Health Phys; 2014 Apr; 106(4):494-504. PubMed ID: 24562070
[TBL] [Abstract][Full Text] [Related]
19.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
20. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
